An observational study in Non-Alcoholic Fatty Liver Disease, sponsored by AdventHealth Translational Research Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by AdventHealth Translational Research Institute · Observational
The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood/urine samples, FibroScan and relevant data will also be collected.
2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.
This study's planned enrollment of 1,250 is above the median of 167 across 681 observational studies indexed under Liver Diseases.
Browse Liver Diseases studies →AdventHealth Translational Research Institute is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults with Non-alcoholic fatty liver disease (NAFLD) and adults without any history of NAFLD.
Biopsy Group Only:
Non-Biopsy Group Only:
Exclusion Criteria
Otherwise, all eligible patients who consent will be included in AVAIL. If participants in the non-biopsy group are found to have NAFLD based on the FibroScan done for this study, then they will be informed of this and advised to follow up with their physician. Their data will still be part of the registry and analyzed with the biopsy group that is found to have NAFLD.
Adults undergoing a standard of care liver biopsy at AdventHealth Central Florida Division for any reason
Procedure: Standard of care liver biopsy · Other: Fibroscan · Other: Biospecimen Collection
Adults without any history of NAFLD
Other: Fibroscan · Other: Biospecimen Collection
Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
Blood and urine will be collected.
Creation of a Biobank of Liver Tissue Paired with a Registry of Histological and Clinical Metadata
Time frame: Baseline
Creation of a Biobank of Blood and Urine Samples Paired with a Registry of Associated Histological and Clinical Metadata
Time frame: Baseline with annual follow up for up to 5 years
Change in Liver Fat and Fibrosis Over Time ad Measured with FibroScan Controlled Attenuation Parameter and Vibration Controlled Transient Elastography, respectively
Time frame: Baseline with annual follow up for up to 5 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AdventHealth Translational Research Institute